Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Pfizer
Elranatamab is a bispecific BCMA-directed CD3 T-cell engaging antibody. It binds BCMA on plasma cells and multiple myeloma cells and CD3 on T-cells, leading to cytolysis of BCMA-expressing cells. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 14, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06152575 | Phase 3 | Multiple Myeloma | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →